Primary biocompatibility tests of poly(lactide-co-glycolide)-(poly-L-orithine/fucoidan) core–shell nanocarriers

Cai, Duanhua; Fan, Jingqian; Wang, Shibin; Long, Ruimin; Zhou, Xizhao; Liu, Yuangang

doi:10.1098/rsos.180320

Cited by 11 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vivo toxicity of the Fucodain-based drug delivery system was evaluated in our previous published paper [46] and demonstrated no obvious lesions in the liver, colon, lung or kidney based on histological analysis four weeks after the treatment of Fucoidan-base nanoparticles. Similar results were reported by Cai et al when assessing the effect of PLGA with layer-by-layer (PLO/fucoidan) NPs on cell viability, acridine orange/ethidium bromide staining, hemolysis, and mouse systemic toxicity of cells and mice [47]. In addition, FPN 3-DTX with fucoidan modification on the surface of hydrophobic PLGA to encapsulate the hydrophobic drug DTX can produce more uniform and smaller particle sizes and also makes it easier for particles to disperse in an aqueous environment compared with PLGA 3-DTX, which is attributed to the higher hydrophilicity of FPN (Figure 2).…”

Section: Discussionsupporting

confidence: 86%

Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

et al. 2020

View full text Add to dashboard Cite

Fucoidan, a natural sulfated polysaccharide, which can activate the immune response and lessen adverse effects, is expected to be an adjuvant agent in combination with chemotherapy. Using natural hydrophilic anticancer polysaccharides to simultaneously encapsulate hydrophobic anticancer drugs is feasible, and a reduced side effect can be achieved to amplify the therapeutic efficacy. In this study, a novel type of fucoidan-PLGA nanocarrier (FPN-DTX) was developed for the encapsulation of the hydrophobic anticancer drug, docetaxel (DTX), as a drug delivery system. From the comparison between FPN-DTX and the PLGA particles without fucoidan (PLGA-DTX), FPNs–DTX with fucoidan were highly stable with smaller sizes and dispersed well without aggregations in an aqueous environment. The drug loading and release can be further modified by modulating relative ratios of Fucoidan (Fu) to PLGA. The (FPN 3-DTX) nanoparticles with a 10:3 ratio of Fu:PLGA displayed uniform particle size with higher encapsulation efficiency than PLGA NPs and sustained drug release ability. The biocompatible fucoidan-PLGA nanoparticles displayed low cytotoxicity without drug loading after incubation with MDA-MB-231 triple-negative breast cancer cells. Despite lower cellular uptake than that of PLGA-DTX due to a higher degree of negative zeta potential and hydrophilicity, FPN 3-DTX effectively exerted better anticancer ability, so FPN 3-DTX can serve as a competent drug delivery system.

show abstract

Section: Discussionsupporting

confidence: 86%

Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Destructive effects on the liver, changes in nutrition and weight were not observed in mice after intraperitoneal injection of these nanoparticles at concentration of 10 mg/mL. The obtained results confirmed that such connection of fucoidan and PLO, not only protected active ingredient, but also improved its biocompatibility [66].…”

Section: Fucoidan Application In the Pharmaceutical Technologymentioning

confidence: 53%

Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms

2019

View full text Add to dashboard Cite

Fucoidan is a polysaccharide built from L-fucose molecules. The main source of this polysaccharide is the extracellular matrix of brown seaweed (Phaeophyta), but it can be also isolated from invertebrates such as sea urchins (Echinoidea) and sea cucumbers (Holothuroidea). Interest in fucoidan is related to its broad biological activity, including possible antioxidant, anti-inflammatory, antifungal, antiviral or antithrombotic effects. The potential application of fucoidan in the pharmaceutical technology is also due to its ionic nature. The negative charge of the molecule results from the presence of sulfate residues in the C-2 and C-4 positions, occasionally in C-3, allowing the formation of complexes with other oppositely charged molecules. Fucoidan is non-toxic, biodegradable and biocompatible compound approved by Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS) category as food ingredient. Fucoidan plays an important role in the pharmaceutical technology, so in this work aspects concerning its pharmaceutical characteristics and designing of various dosage forms (nanoparticles, liposomes, microparticles, and semisolid formulations) with fucoidan itself and with its combinations with other polymers or components that give a positive charge were reviewed. Advantages and limitations of fucoidan utilization in the pharmaceutical technology were also discussed.

show abstract

“…To measure released hemoglobin, the absorbance at 545 nm of the supernatants was measured using the microplate reader. The percentage of hemolysis was calculated according to the following equation [ 41 ].

where OD is optical density.…”

Section: Methodsmentioning

confidence: 99%

Hemocompatibility Evaluation of Thai Bombyx mori Silk Fibroin and Its Improvement with Low Molecular Weight Heparin Immobilization

et al. 2022

View full text Add to dashboard Cite

Bombyx mori silk fibroin (SF), from Nangnoi Srisaket 1 Thai strain, has shown potential for various biomedical applications such as wound dressing, a vascular patch, bone substitutes, and controlled release systems. The hemocompatibility of this SF is one of the important characteristics that have impacts on such applications. In this study, the hemocompatibility of Thai SF was investigated and its improvement by low molecular weight heparin (LMWH) immobilization was demonstrated. Endothelial cell proliferation on the SF and LMWH immobilized SF (Hep/SF) samples with or without fibroblast growth factor-2 (FGF-2) was also evaluated. According to hemocompatibility evaluation, Thai SF did not accelerate clotting time, excess stimulate complement and leukocyte activation, and was considered a non-hemolysis material compared to the negative control PTFE sheet. Platelet adhesion of SF film was comparable to that of the PTFE sheet. For hemocompatibility enhancement, LMWH was immobilized successfully and could improve the surface hydrophilicity of SF films. The Hep/SF films demonstrated prolonged clotting time and slightly lower complement and leukocyte activation. However, the Hep/SF films could not suppress platelet adhesion. The Hep/SF films demonstrated endothelial cell proliferation enhancement, particularly with FGF-2 addition. This study provides fundamental information for the further development of Thai SF as a hemocompatible biomaterial.

show abstract

Primary biocompatibility tests of poly(lactide-co-glycolide)-(poly-L-orithine/fucoidan) core–shell nanocarriers

Cited by 11 publications

References 27 publications

Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms

Hemocompatibility Evaluation of Thai Bombyx mori Silk Fibroin and Its Improvement with Low Molecular Weight Heparin Immobilization

Contact Info

Product

Resources

About